Waters(WAT) Prnewswire·2025-02-12 11:00Core Insights - Waters Corporation reported fourth quarter 2024 sales of 819 million in the same quarter of 2023, with a 2% negative impact from currency translation [1][4] - The company achieved a GAAP diluted EPS of 3.65 in Q4 2023, while non-GAAP EPS increased by 13% to 3.62 in the prior year [2][14] - Full-year 2024 sales were 2,956 million in 2023, with currency translation negatively impacting sales by approximately 1% [6][14] Fourth Quarter 2024 Performance - Sales in the pharmaceutical market rose by 8% as reported and 10% in constant currency, while industrial market sales increased by 1% as reported and 2% in constant currency [4] - Instrument system sales grew by 6% as reported and 8% in constant currency, and recurring revenues increased by 7% as reported and 9% in constant currency [5] - Geographically, sales in Asia increased by 4% as reported and 9% in constant currency, while sales in the Americas and Europe grew by 6% and 10% respectively [5] Full-Year 2024 Overview - The company reported a GAAP EPS of 10.84 in 2023, while non-GAAP EPS increased by 1% to 762 million, with free cash flow of 12.70 and $13.00, accounting for an estimated 4% headwind from unfavorable foreign exchange [10][36] - For the first quarter of 2025, the company anticipates constant currency sales growth of 4.0% to 7.0%, with a currency translation impact expected to decrease growth by approximately 3.0% [11][12]